^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Fallopian Tube Cancer |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) + Zejula (niraparib) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
Acceptable Recurrence Therapies for…Fallopian tube cancer: Targeted Therapy...Niraparib/Bevacizumab
